Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Quantitative analysis of complex drug-drug interactions (DDIs) between cerivastatin and inhibitors using physiologically based pharmacokinetic (PBPK) modeling

Yoshiaki Yao, Kota Toshimoto, Soo-Jin Kim, Takashi Yoshikado and Yuichi Sugiyama
Drug Metabolism and Disposition April 30, 2018, dmd.117.079210; DOI: https://doi.org/10.1124/dmd.117.079210
Yoshiaki Yao
1 Astellas Pharma Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kota Toshimoto
2 Sugiyama Laboratory, RIKEN Innovation Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soo-Jin Kim
2 Sugiyama Laboratory, RIKEN Innovation Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Yoshikado
2 Sugiyama Laboratory, RIKEN Innovation Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuichi Sugiyama
2 Sugiyama Laboratory, RIKEN Innovation Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ychi.sugiyama@riken.jp

Data Supplement

  • Supplemental Data -

    Supplemental Figure 1 - Fitted blood concentration-time profile of cyclosporine A (CsA)

    Supplemental Figure 2 - Fitted blood concentration-time profile of cerivastatin (CER) under control conditions in the study of DDI with CsA (A) (0.2 mg CER was administered on day 6) or with gemfibrozil (GEM) (B) (0.3 mg CER was administered on day 3)

    Supplemental Figure 3 - Simulated blood concentration-time profiles of CER under control and DDI conditions using the geometric mean of in vitro inhibition constants after the optimization of model parameters to explain PK

    data under control conditions (Supplemental Table 5) (Kim et al., 2017)

    Supplemental Figure 4 - Sensitivity analyses of the in vitro parameters of CER and CsA under DDI conditions with CsA (multiple oral administration, 111 mg (fitted value, same as Supplemental Fig. 3(A)) twice a day for 6 days) after single oral administration of 0.2 mg CER on day 6

    Supplemental Figure 5 - Sensitivity analyses of the in vitro parameters of CER and GEM/GEM-glu under DDI conditions with GEM (multiple oral administration, 600 mg twice a day for 3 days) after single oral administration of 0.3 mg CER on day 3

    Supplemental Figure 6 - Simulated blood concentration-time profile of CER under control and DDI conditions with GEM (600 mg of GEM was orally administered twice a day for 3 days) using the best-fit in vitro parameter sets (Table

    3) after the sensitivity analyses (Figs. 5 and 6) of model parameters to explain PK data under DDI conditions

    Supplemental Figure 7 - Simulated blood concentration-time profiles of cerivastatin under control and DDI conditions with cyclosporine A in each liver model using the geometric mean of in vitro inhibition constants after the

    optimization of model parameters to explain PK data under control conditions (Supplemental Table 5; Ki_OATP1B1 and Ki_CYP3A4 were 0.024 μM and 3.71 μM, respectively.)

    Supplemental Figure 8 - The results of PBPK analyses of CER in the model without EHC

    Supplemental Table 1 - Pharmacokinetic parameters for cerivastatin (CER)

    Supplemental Table 2 - Optimized parameter values of cyclosporine A (CsA) after the fitting analysis by Napp

    Supplemental Table 3 - Pharmacokinetic parameters for gemfibrozil (GEM)/gemfibrozil 1-O-β-glucuronide (GEM-glu)

    Supplemental Table 4 - A) Optimized parameters of CER in the DDI study with CsA under control conditions after the fitting analysis by Napp

    Supplemental Table 5 - Summary of in vitro inhibition constants reported by Kim et al. (Kim et al., 2017)

    Supplemental Table 6 - Average, SD and CV% of the 30 most-optimized drug-dependent parameter sets of CER

    in 1- and 3-liver models selected to minimize the WSS from the observed i.v. and p.o. data after the optimization of model parameters by CNM to explain the PK data under i.v. conditions

    Supplemental Table 7 - Optimized parameters of CER in the DDI study with CsA under control conditions after the fitting analysis by Napp

    Supplemental Table 8 - Optimized parameters of CsA after the fitting analysis by Napp in 1- and 3-liver models

    Supplemental Table 9 - Average, SD and CV% of the 30 most-optimized drug-dependent parameter sets of CER

    in the model without EHC selected to minimize the WSS from the observed i.v. and p.o. data after the optimization of model parameters by CNM to explain the PK data under i.v. conditions

    Supplemental Table 10 - Optimized parameters of CER in the DDI study with CsA under control conditions after the fitting analysis by Napp in the model without EHC

    References

    Model equations for cerivastatin (CER)

  View article

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics